ReproCELL Incorporated [4978.T]
TOKYO, May 14 (Pulse News Wire) – ReproCELL Incorporated (4978.T) reported non-operating revenue and foreign exchange gains for its fiscal year ending March 31, 2026. For the fiscal year, the company recorded non-operating income totaling ¥99 million.
This includes government grants amounting to ¥99 million related to two research projects funded by the National Institutes of Biomedical Innovation, Health, and Nutrition (AMED). The grant was confirmed on December 5, 2025, and received during the accounting period.
Additionally, ReproCELL recognized a foreign exchange gain of ¥109 million due to fluctuations in foreign currency balances held by the company. This gain primarily resulted from revaluation adjustments based on the exchange rates at the end of the reporting period.
These figures contribute to the overall financial performance of ReproCELL for the fiscal year, reflecting both governmental support and favorable currency movements.
🟢 Confidence: High AI-translated content.